middle.news
How Will Prescient’s $6.8M Raise Accelerate PTX-100’s Cancer Fight?
10:13am on Tuesday 29th of July, 2025 AEST
•
Healthcare
Read Story
How Will Prescient’s $6.8M Raise Accelerate PTX-100’s Cancer Fight?
10:13am on Tuesday 29th of July, 2025 AEST
Key Points
Raised $6.8 million via Share Purchase Plan at $0.04 per share
Initiated follow-on placement at same discounted price, 11.1% below last trade
Funds to support Phase 2 clinical trial of PTX-100, a first-in-class GGT-1 inhibitor
PTX-100 holds FDA Orphan Drug and Fast Track designations for T cell lymphomas
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE